Elizabeth Masson-Hurlburt Net Worth

The estimated Net Worth of Elizabeth Masson Hurlburt is at least $796 mil dollars as of 5 December 2018. Ms Hurlburt owns over 40,000 units of CorMedix Inc stock worth over $276,400 and over the last 7 years she sold CRMD stock worth over $55,360. In addition, she makes $463,853 as Exec. VP & Head of Clinical Operations at CorMedix Inc.

Ms Hurlburt CRMD stock SEC Form 4 insiders trading

Ms has made over 2 trades of the CorMedix Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 8,000 units of CRMD stock worth $55,360 on 21 May 2021.

The largest trade she's ever made was exercising 40,000 units of CorMedix Inc stock on 5 December 2018 worth over $11,600. On average, Ms trades about 4,800 units every 90 days since 2018. As of 5 December 2018 she still owns at least 40,000 units of CorMedix Inc stock.

You can see the complete history of Ms Hurlburt stock trades at the bottom of the page.

Ms. Elizabeth Masson-Hurlburt biography

Elizabeth Masson-Hurlburt is the Exec. VP & Head of Clinical Operations at CorMedix Inc.

What is the salary of Ms Hurlburt?

As the Exec. VP & Head of Clinical Operations of CorMedix Inc, the total compensation of Ms Hurlburt at CorMedix Inc is $463,853. There are 6 executives at CorMedix Inc getting paid more, with Khoso Baluch having the highest compensation of $1,795,830.

How old is Ms Hurlburt?

Ms Hurlburt is 42, she's been the Exec. VP & Head of Clinical Operations of CorMedix Inc since . There are 12 older and 1 younger executives at CorMedix Inc. The oldest executive at CorMedix Inc is John L. Armstrong Jr., 76, who is the Exec. VP for Technical Operations.

What's Ms Hurlburt's mailing address?

Elizabeth's mailing address filed with the SEC is C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 15 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish, eBrian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Ms Hurlburt stock trades at CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer